Sangamo R&D chief hits the exit as it splits R&D into separate units

A week after presenting updated data from its Pfizer-partnered bleeding disorder gene therapy, Sangamo is making some big changes to its R&D.

First up, the biotech will be splitting its research and development into two “separate functions,” it said in a statement, and will seek out a new head of development to lead the latter. The former will in the interim be led by Jason Fontenot, senior vice president of cell therapy.